Pharmacogenomics
Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues
Gillis NK & Innocenti F Clin Pharmacol Ther 2014 Dec;96(6):655-7
Gillis NK & Innocenti F Clin Pharmacol Ther 2014 Dec;96(6):655-7
Meaningful use of pharmacogenetics![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_sTOQXSz98DkiVr599EHle6XoRFsNJKsms-6eK7JZXK2xMEh4thMlRSTLMSBlaucQCBeW87KGynLIASkyNRbuxjTv3aussFzSE6feLWtJAJ_GJDNzJ-NJ1W=s0-d)
M J Ratain and J A Johnson Clinical Pharmacology & Therapeutics (2014); 96 6, 650–652.
M J Ratain and J A Johnson Clinical Pharmacology & Therapeutics (2014); 96 6, 650–652.
Useless until proven effective: The clinical utility of preemptive pharmacogenetic testing![External Web Site Icon External Web Site Icon](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_sTOQXSz98DkiVr599EHle6XoRFsNJKsms-6eK7JZXK2xMEh4thMlRSTLMSBlaucQCBeW87KGynLIASkyNRbuxjTv3aussFzSE6feLWtJAJ_GJDNzJ-NJ1W=s0-d)
A C J W Janssens and P A Deverka Clinical Pharmacology & Therapeutics (2014); 96 6, 652–654.
A C J W Janssens and P A Deverka Clinical Pharmacology & Therapeutics (2014); 96 6, 652–654.
No hay comentarios:
Publicar un comentario